Toxicology Drug Screening Market

Executive Summary

Toxicology Drug Screening Market was valued at US $5.60 billion in 2021 and is projected to grow at 7.13% CAGR over the forecast period to reach US $8.47 billion by 2027. Toxicology Drug Screening Market represented US $0.72 billion opportunity over 2019-2021 and estimated to create US $2.87 billion opportunity in 2027 over 2021.

Toxicology Drug Screening from Consainsights analyses the Toxicology Drug Screening Market in the Life Sciences industry over the forecast period to 2027.

Toxicology Drug Screening research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Toxicology Drug Screening segmentation includes Testing Type, Product, Application and Geography.

Based on the Testing Type, the Toxicology Drug Screening analysis covers In vitro, In vivo, In silico.

In Testing Type segment, In vitro segment has highest cagr growth of 6.31%.

Based on the Product, the Toxicology Drug Screening analysis covers Instruments, Reagents and Consumables, Animal Models, Softwares, Other Products.

In Product segment, Instruments segment has highest cagr growth of 6.31%.

Based on the Application, the Toxicology Drug Screening analysis covers Immunotoxicity, Systemictoxicity, Developmental and Reproductive Toxicity (DART), Endocrine Disruption, Other Applications.

In Application segment, Immunotoxicity segment has highest cagr growth of 6.31%.

Based on the region, the Toxicology Drug Screening analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Agilent Technologies, Inc, Bio-Rad Laboratories Inc., BioReliance Inc. (Merck), Charles River Laboratories International Inc., Enzo Life Sciences Inc., Eurofins Scientific, Danaher, Laboratory Corporation of America Holdings, Promega Corporation, The Jackson Laboratory, Thermo Fisher Scientific Inc., Wuxi AppTec, Waters, Selvita, TECHCOMP GROUP (SCION INSTRUMENTS) and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Testing Type

Introduction

In 2021, In vitro segment has the highest revenue of US $3.34 billion and is expected to grow at CAGR of 6.31% by 2027 In vitro segment has highest cagr growth of 6.31%.

In vitro

In vitro segment was valued at US $2.91 billion in 2019 and is projected to grow at 6.31% CAGR over the forecast period to reach US $5.05 billion by 2027. In vitro segment represented US $0.43 billion opportunity over 2019-2021 and estimated to create US $1.71 billion opportunity in 2027 over 2021.

In vivo

In vivo segment was valued at US $0.97 billion in 2019 and is projected to grow at 6.31% CAGR over the forecast period to reach US $1.69 billion by 2027. In vivo segment represented US $0.14 billion opportunity over 2019-2021 and estimated to create US $0.57 billion opportunity in 2027 over 2021.

In silico

In silico segment was valued at US $1.00 billion in 2019 and is projected to grow at 6.31% CAGR over the forecast period to reach US $1.73 billion by 2027. In silico segment represented US $0.15 billion opportunity over 2019-2021 and estimated to create US $0.59 billion opportunity in 2027 over 2021.

Product

Introduction

In 2021, Instruments segment has the highest revenue of US $2.31 billion and is expected to grow at CAGR of 6.31% by 2027 Instruments segment has highest cagr growth of 6.31%.

Instruments

Instruments segment was valued at US $2.02 billion in 2019 and is projected to grow at 6.31% CAGR over the forecast period to reach US $3.50 billion by 2027. Instruments segment represented US $0.30 billion opportunity over 2019-2021 and estimated to create US $1.18 billion opportunity in 2027 over 2021.

Reagents and Consumables

Reagents and Consumables segment was valued at US $1.23 billion in 2019 and is projected to grow at 6.31% CAGR over the forecast period to reach US $2.14 billion by 2027. Reagents and Consumables segment represented US $0.18 billion opportunity over 2019-2021 and estimated to create US $0.72 billion opportunity in 2027 over 2021.

Animal Models

Animal Models segment was valued at US $0.75 billion in 2019 and is projected to grow at 6.31% CAGR over the forecast period to reach US $1.30 billion by 2027. Animal Models segment represented US $0.11 billion opportunity over 2019-2021 and estimated to create US $0.44 billion opportunity in 2027 over 2021.

Softwares

Softwares segment was valued at US $0.51 billion in 2019 and is projected to grow at 6.31% CAGR over the forecast period to reach US $0.88 billion by 2027. Softwares segment represented US $0.08 billion opportunity over 2019-2021 and estimated to create US $0.30 billion opportunity in 2027 over 2021.

Other Products

Other Products segment was valued at US $0.37 billion in 2019 and is projected to grow at 6.31% CAGR over the forecast period to reach US $0.65 billion by 2027. Other Products segment represented US $0.06 billion opportunity over 2019-2021 and estimated to create US $0.22 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, Immunotoxicity segment has the highest revenue of US $2.27 billion and is expected to grow at CAGR of 6.31% by 2027 Immunotoxicity segment has highest cagr growth of 6.31%.

Immunotoxicity

Immunotoxicity segment was valued at US $1.98 billion in 2019 and is projected to grow at 6.31% CAGR over the forecast period to reach US $3.43 billion by 2027. Immunotoxicity segment represented US $0.29 billion opportunity over 2019-2021 and estimated to create US $1.16 billion opportunity in 2027 over 2021.

Systemictoxicity

Systemictoxicity segment was valued at US $1.11 billion in 2019 and is projected to grow at 6.31% CAGR over the forecast period to reach US $1.92 billion by 2027. Systemictoxicity segment represented US $0.16 billion opportunity over 2019-2021 and estimated to create US $0.65 billion opportunity in 2027 over 2021.

Developmental and Reproductive Toxicity (DART)

Developmental and Reproductive Toxicity (DART) segment was valued at US $0.77 billion in 2019 and is projected to grow at 6.31% CAGR over the forecast period to reach US $1.34 billion by 2027. Developmental and Reproductive Toxicity (DART) segment represented US $0.11 billion opportunity over 2019-2021 and estimated to create US $0.45 billion opportunity in 2027 over 2021.

Endocrine Disruption

Endocrine Disruption segment was valued at US $0.64 billion in 2019 and is projected to grow at 6.31% CAGR over the forecast period to reach US $1.12 billion by 2027. Endocrine Disruption segment represented US $0.10 billion opportunity over 2019-2021 and estimated to create US $0.38 billion opportunity in 2027 over 2021.

Other Applications

Other Applications segment was valued at US $0.37 billion in 2019 and is projected to grow at 6.31% CAGR over the forecast period to reach US $0.65 billion by 2027. Other Applications segment represented US $0.06 billion opportunity over 2019-2021 and estimated to create US $0.22 billion opportunity in 2027 over 2021.